GlassScriptPhysician profile
Sanjay J Mathew
NPI 1023140332
$133,584.73
in general payments reported to CMS, 2019-2025
16 companies · $4,337 in 2025
The $4,337 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $10K · 2021: $2,825 · 2022: $9,009 · 2023: $28K · 2024: $16K · 2025: $4,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $35K · Honoraria: $6,750 · Travel and Lodging: $4,780 · Food and Beverage: $1,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $34,815.00 |
| Honoraria | $6,750.00 |
| Travel and Lodging | $4,780.40 |
| Food and Beverage | $1,359.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $60,395.46 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12,741.22 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $12,513.47 | 2023-2024 | |
| Livanova USA, INC. | $8,342.16 | 2023-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Allergan, INC. | $7,163.06 | 2019 | |
| Sumitomo Pharma America, INC. | $6,800.00 | 2023-2024 | |
| Sage Therapeutics, LLC | $5,957.50 | 2020-2022 | |
| Almatica Pharma LLC | $4,284.24 | 2022 | |
| Abbott Laboratories | $3,882.62 | 2024 | Infinity, Proclaim |
| Greenwich Biosciences, INC. | $3,000.00 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $2,100.00 | 2022 | |
| Neurocrine Biosciences, INC. | $1,750.00 | 2020-2021 | |
| Neos Therapeutics, LP | $1,725.00 | 2025 | Exxua |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,700.00 | 2024 | |
| Sunovion Pharmaceuticals INC. | $1,230.00 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.